Publisher： John Wiley & Sons Inc
E-ISSN： 1365-2141|162|2|229-239
ISSN： 0007-1048
Source： BRITISH JOURNAL OF HAEMATOLOGY, Vol.162, Iss.2, 2013-07, pp. : 229-239
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
SummaryPatients with myelofibrosis (MF) have significant debilitating symptoms, physical disabilities, and poor health‐related quality of life (HRQoL). Here, we report post‐hoc analyses of the impact of ruxolitinib, a potent and selective JAK1 and JAK2 inhibitor, on disease‐related symptoms and HRQoL in MF patients from the large phase 3 COMFORT‐II study (N = 219). During the follow‐up period of 48 weeks, HRQoL and MF‐associated symptoms improved from baseline for ruxolitinib‐treated patients but remained the same or worsened for best available therapy (BAT)‐treated patients. Based on the European Organization for Research and Treatment of Cancer QoL Questionnaire core 30 items (EORTC QLQ‐C30), treatment‐induced differences in physical and role functioning, fatigue, and appetite loss significantly favoured ruxolitinib versus BAT from week 8 (P < 0·05) up to week 48 (P < 0·05). Ruxolitinib resulted in significantly higher response rates in global health status/QoL and Functional Assessment of Cancer Therapy‐Lymphoma (FACT‐Lym) summary scores versus BAT at most time points (P < 0·05). Significant improvements in the Lymphoma subscale (including symptoms of pain, fever, itching, fatigue, weight loss, loss of appetite, and other patient concerns), FACT‐General, FACT‐Lym trial outcome index, and FACT‐Lym total were also observed with ruxolitinib versus BAT starting at week 8 and continuing thereafter. Overall, these data demonstrated that ruxolitinib improved HRQoL in MF patients and further support the use of ruxolitinib for the treatment of symptomatic MF.
Related content
Access to resources
Recommend
By Campone Mario Beck J. Thaddeus Gnant Michael Neven Patrick Pritchard Kathleen I. Bachelot Thomas Provencher Louise Rugo Hope S. Piccart Martine Hortobagyi Gabriel N. Nunzi Martina Heng Daniel Y.C. Baselga José Komorowski Anna Noguchi Shinzaburo Horiguchi Jun Bennett Lee Ziemiecki Ryan Zhang Jie Cahana Ayelet Taran Tetiana Sahmoud Tarek Burris Howard A.
Current Medical Research and Opinion, Vol. 29, Iss. 11, 2013-11 ,pp. :
Alexithymia and Health-Related Quality of Life in Patients with Dizziness
Psychopathology, Vol. 46, Iss. 6, 2012-12 ,pp. :